Syntab Therapeutics is a German biotech company based in Würselen near Aachen, founded in 2010. Specializing in immuno-oncology therapies, Syntab harnesses the innate immune system to target and destroy cancer cells, providing sustained anti-cancer benefits to patients. The company's advanced technology platform demonstrates exceptional precision across various cancer-related targets. Syntab employs a streamlined management strategy and collaborates closely with esteemed academic partners, such as Prof. Christian Becker’s team in Vienna and Aachen University, to conduct preclinical studies. With a focus on Biotechnology and Health Care industries, Syntab's innovative approach and academic collaborations position the company for potential success in the field of immuno-oncology therapies.
There is no investment information
No recent news or press coverage available for Syntab Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.